Developing a new treatment for ulcerative colitis that targets the gut
Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis
['FUNDING_SBIR_2'] · VIVREON BIOSCIENCES, LLC · NIH-11007576
This study is working on a new medicine to help people with ulcerative colitis by specifically targeting the inflammation in their gut, aiming to provide better relief for those who haven't found success with current treatments.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VIVREON BIOSCIENCES, LLC (nih funded) |
| Locations | 1 site (San Diego, UNITED STATES) |
| Trial ID | NIH-11007576 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a novel therapeutic agent specifically designed to treat ulcerative colitis (UC) by targeting the inflammation in the gut. The approach involves developing a drug that selectively acts on the inner lining of the colon and rectum, where inflammation occurs, while minimizing systemic side effects. By utilizing a mechanism that restricts the action of the drug to the gut, the research aims to improve treatment efficacy for patients who do not respond to existing therapies. The study will explore the role of CRAC channels in gut immune cells to better understand how to control inflammation effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with ulcerative colitis who have not responded well to current treatments.
Not a fit: Patients with ulcerative colitis who are already effectively managing their condition with existing therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with ulcerative colitis, potentially improving their quality of life.
How similar studies have performed: Other research has shown promise in targeting localized inflammation in various conditions, suggesting that this approach could be effective for ulcerative colitis as well.
Where this research is happening
San Diego, UNITED STATES
- VIVREON BIOSCIENCES, LLC — San Diego, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GREENBERG, MILTON L — VIVREON BIOSCIENCES, LLC
- Study coordinator: GREENBERG, MILTON L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Animal Disease Models